Navigation Links
Sequella and NIH Sign Exclusive Worldwide Licensing Agreement for SQ109 for New Infectious Disease Indications
Date:11/16/2009

ella

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

About NIAID and NIH

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

The National Institutes of Health (NIH)--The Nation's Medical Research Agency--includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law. The content of this release does not necessarily represent the official views of the Na
'/>"/>

SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
2. Sequella Receives SBIR Funding Grant from the NIH for Further Development of Tuberculosis Drug SQ609
3. Infectious Diseases Company, Sequella, to Present at Upcoming European Conferences
4. Sequella Commences Phase 1B Study for New Tuberculosis Drug SQ109
5. Sequella Obtains Funding to Continue Expansion of its Anti-infectives Pipeline
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. International Isotopes Inc. Announces Completion of an Exclusive Distributor Agreement for Sales of New Style Transportation Containers
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
10. Vet-Stem and Central Veterinary Research Labs of Dubai Sign Exclusive License
11. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research Triangle Park, NC (PRWEB) March 05, 2015 ... Entegrion, Inc., announced that Pierre Noel, M.D., Professor ... been elected to the Company’s Board of Directors. ... Mowell said, “We are extremely fortunate to have ... with the country’s leading healthcare organization, join Entegrion’s ...
(Date:3/5/2015)... , March 5, 2015  In response to ... Miami, FL on February 12, ... both of strong financial health and their SUDOSCAN® devices ... research has indicated. Furthermore, Impeto prefers to have the courts ... There are more than 40 articles written by Key ...
(Date:3/4/2015)... 2015 PDL BioPharma, Inc. (PDL) (NASDAQ: ... the: , 3.75% Convertible Senior Notes due May ... stock per $1,000 principal amount or approximately $5.72 per share, ... the note is adjusted in connection with the regular quarterly ... all stockholders who own shares of PDL on March 5, 2015, ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 USDM ... in the life sciences industry, hired David Blewitt ... the Cloud Compliance Services and Solutions at USDM ... cloud based applications while maintaining compliance with government regulations ... has been an accomplished life sciences regulatory and IS ...
Breaking Biology Technology:Entegrion Announces Appointment of Pierre Noel, MD, to Its Board of Directors 2Impeto Medical Responds to Published Allegations by LD Technology LLC ("LD") 2PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 2USDM Life Sciences Names David Blewitt VP of Cloud Compliance for Regulated Life Sciences 3
... N.J., Feb. 15 Osteotech, Inc.,(Nasdaq: OSTE ... and year,ended December 31, 2007 financial results will ... will be conducted by Sam Owusu-Akyaw,President and Chief ... management, on Wednesday, February 20, 2008, at 9:00 ...
... 15 OrbusNeich,s Genous(TM),Bio-engineered R stent(TM) is feasible and ... to a paper published in the American,Heart Journal (2008; ... on a study of 120 acute ST-elevation myocardial,infarction (STEMI) ... incidence of late thrombosis and that the revascularization rate ...
... and Medical Affairs, NEW YORK, Feb. 15 ... Lou DeBergalis has joined the,Company as Vice President, Quality ... the Company later this month in the role of,Vice ... will,report directly to Michael S. Weiss, Chief Executive Officer., ...
Cached Biology Technology:OrbusNeich's Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports 2Keryx Biopharmaceuticals Announces Additions to Management Team 2Keryx Biopharmaceuticals Announces Additions to Management Team 3Keryx Biopharmaceuticals Announces Additions to Management Team 4
(Date:3/3/2015)... Calif. , March 3, 2015 /PRNewswire/ ... leading provider of advanced cryogenic logistics solutions ... including immunotherapies, stem cells, cell lines, clinical ... reproductive medicine, today announced the expansion of ... Research Centers, ("Fred Hutch") Clinical Research ...
(Date:3/2/2015)... 2, 2015  Businesses have a new option ... Tharon Rankins Enterprises has announced the launch of ... way for businesses to protect their customers, personal ... Beconux is a biometric transaction processing ... similarly to an ATM machine, the new system ...
(Date:2/25/2015)... Ark. , Feb. 25, 2015  ABC ... and billing in the Health and Fitness Industry, ... well as to MYiCLUBonline.  The latest upgrade includes ... the inclusion of cardless check-in via Identity One ... the first time through interactive displays at the ...
Breaking Biology News(10 mins):Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Personal Data Protection Company Launches New Product 2ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... 2011)Roux-en-Y gastric bypass, the most common type of bariatric ... most effective therapy for morbid obesity. Patients who undergo ... a small pouch and connected to the middle of ... However, the reasons behind this surgery,s success have been ...
... what to eat for dinner. Should it be the chicken ... just get some Rocky Road? Making that choice, it ... researchers from the California Institute of Technology (Caltech), it,s one ... toward the healthy side of life. And that shift may ...
... and Biological Sciences Research Council and the French Institut ... ground beetles reduce the amount of weed seeds in ... support the need to conserve farmland biodiversity as it ... weeds and improving food security. This research confirms ...
Cached Biology News:Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 2Study suggests weight loss from gastric bypass may be partly due to dietary fat aversion 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 2Think healthy, eat healthy: Caltech scientists show link between attention and self-control 3Think healthy, eat healthy: Caltech scientists show link between attention and self-control 4Beetles play an important role in reducing weeds 2
...
Mouse monoclonal antibody raised against a partial recombinant PUM2. NCBI Entrez Gene ID = PUM2...
... Cloning Kit enables you to prepare, in ... primary cosmid library of genomic DNA for ... High efficiency cosmid library construction is accomplished ... First, genomic DNA is randomly sheared by ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: